Украински учени са открили микроорганизъм, борещ се с раковите клетки
14 април 2011 | 14:52 | Агенция "Фокус"Начало / Свят
Киев. Учени от Института за клетъчна биология в град Лвов са открили микроорганизъм, който разгражда ракови клетки.
„Изследваме микроорганизма, наречен Аргенина (Argenina) от дълго време. И стигнахме до заключението, че той може да се бори с клетките на рака”, е съобщил пред агенция Укринформ Андрий Сибирни, директор на института.
Сибирни допълни, че в момента учените работят върху методологията за прилагане на организма в заболелите клетки.
Новата технология се пази в тайна, като украинските експерти обещават да я представят след получаването на практически резултати.
По данни на Световната здравна организация (СЗО) ракът е причина за 13 % от смъртните случаи по света. Повече от половин милион души, или около 2 % от населението, страдат от форма на рак в Украйна.Източник: http://focus-news.net/?id=n1513818
МЕДИЦИНСКИ ДОКЛАДИ ПО ТЕМАТА
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC154404/
J Bacteriol. 2003 May; 185(9): 2683–2686.
PMCID: PMC154404
Microorganisms and Cancer: Quest for a Therapy
This article has been cited by other articles in PMC.
Many microorganisms are known to cause cancer. Some examples are Helicobacter pylori, which causes gastric cancer in humans and animals (6), and Agrobacterium tumefaciens, which causes crown gall in plants (37).
The use of microorganisms or their products in the treatment of cancer
is, however, less widely known, particularly among the readership of the
Journal of Bacteriology, as most of these papers are published in more
medically oriented journals and very few relevant papers have been
published in the Journal of Bacteriology.
Live bacteria in the treatment of cancer.
The
use of bacteria or their extracts in the treatment of cancer goes back
more than 100 years. The most cited case is that by the physician and
surgeon William B. Coley of the then Memorial Hospital in New York City,
now called Memorial Sloan-Kettering Hospital, who observed that many of
his patients with various forms of cancer had their tumors regress when
they were infected with bacterial pathogens. Treatment to eliminate the
infections allowed the cancer to come back (5, 19).
He developed a treatment modality by making extracts of some of these
bacteria, later described as Coley's toxin, which he used to help shrink
the tumors in his patients (5, 19).
Subsequently, many bacteria have been used in an effort to reduce the
growth rate or size of tumors. The most prominent example would be the
use of Mycobacterium bovis BCG, the vaccine strain, in the
treatment of bladder cancer. Several well-coordinated studies have shown
a clear relationship between the use of M. bovis BCG
immunoprophylaxis after surgical removal of the tumor and the decreased
recurrence rate or the delayed period during which recurrence could
occur (15, 18).
The long-term use of high titers of BCG with booster shots poses
problems, such as side effects, lack of predictability of its
effectiveness, and rare cases of sepsis, leading to the deaths of
patients, so new ways of administering BCG have often been discussed (20).
The mode of action of BCG to exert its antineoplastic effect is
believed to be due to its effect on the immune system, with CD4 and CD8 T
lymphocytes playing a major role (27),
although the intravesical instillation of BCG is thought to result in
nonspecific cystitis, which is likely accompanied by the local
production of cytokines and the accumulation of inflammatory cells that
are more damaging to the malignant rather than normal cells (2).
The requirement of live cells of BCG for its anticancer activity is
reflected in the fact that monocytes and T helper type 1 cells are often
important for its effectiveness (34)
and that large doses of vitamins that presumably enhance BCG survival
and proliferation have a positive effect on the treatment of bladder
cancer in human clinical trials (16). Similar positive effects have also been reported to be seen with immunoadjuvants such as tumor necrosis factor alpha (12). Using a human in vitro system to analyze the role of NK cells in BCG-induced cellular cytotoxicity, Brandau et al. (3)
treated mononuclear cells with BCG for 7 days and demonstrated the
ability of the BCG-activated killer cells to significantly destroy
bladder tumor cells. Similarly, using C57BL/6 wild-type mice,
NK-deficient beige mice, and mice treated with anti-NK1.1 monoclonal
antibody, these authors noticed that viable BCG cells significantly
prolonged survival in wild-type mice compared with control nontreated
mice while BCG therapy was completely ineffective in NK-deficient beige
mice or in mice treated with anti-NK1.1 monoclonal antibody (3).
These studies demonstrated a key role for NK cells in BCG
immunotherapy. BCG cell wall skeleton stimulation of the human innate
immune system, as judged by altered levels of interleukin-12 (IL-12),
IL-18, IL-10, and gamma interferon in the blood lymphocytes of patients
with lung cancer, also demonstrated a role of BCG in the modulation of
immune system activation (17).
It should be emphasized, however, that the cancer that shows the
maximal response to BCG treatment is superficial bladder cancer. Similar
effects that are statistically significant have not been observed with
other forms of cancer such as lung cancer (30) or melanoma (1).
The reasons for such differential effects are not clear, although it is
possible that certain forms of malignancies such as bladder cancer are
more susceptible to BCG treatment because of cytokine network modulation
or of the functional T-lymphocyte receptor repertoire expressed by
surrounding tissues, recruited cells, or the malignant cells themselves.
While M. bovis
BCG has been used to bolster the immune system against specific cancers
such as bladder cancer, attenuated bacterial vaccine vectors such as Listeria monocytogenes and Salmonella enterica
serovar Typhimurium that target the antigen-presenting cells or are
powerful inducers of an innate immune response and immune mediators such
as IL-12 have also been recommended for use in cancer prevention and
therapy (21, 22). However, facultative anaerobic bacteria such as Salmonella are also known to target tumor cells for growth and proliferation (10) and attenuated Salmonella
mutants, when injected intraperitoneally in plasmacytoma-bearing mice,
were reported to allow tumor regression and prolonged survival of the
mice (8). Similar use of Shigella (31) and Clostridia (9) species for the delivery of therapeutic agents to target cells,including tumor cells, has been reported. S. enterica
serovar Typhimurium by far has attracted considerable attention because
it is a facultative anaerobe capable of growing under both aerobic and
anaerobic conditions and is highly manipulable genetically. Salmonella also targets tumors specifically for growth, with titers in tumors far exceeding those in the liver, the normal site of Salmonella replication in non-tumor-bearing mice. With attenuated Salmonella, the tumor-liver titers were shown to range between 250:1 and 9,000:1 (25). Such a propensity of Salmonella
to target tumor cells for proliferation was shown to allow tumor
regression, prolonging the survival of melanoma-tumor-harboring mice
when injected intraperitoneally into the mice (25, 33). To investigate the role of Salmonella pathogenicity islands in tumor regression, Pawelek et al. (24) examined the effect of various Salmonella
mutants defective in pathogenicity island genes on systemic invasion
and survival in various cell types in mice. They demonstrated that Salmonella pathogenicity island 2 is essential for Salmonella antitumor effects, perhaps by aiding bacterial amplification within the tumors. The oral route of vaccination via Salmonella as the vector was used by Weth et al. (36)
to compare a cytotoxic-T-lymphocyte- versus T-helper-cell-directed
vaccination approach. Mice were vaccinated either orally with attenuated
S. enterica serovar Typhimurium or subcutaneously with
dendritic cells loaded with gp100 peptides predicted to bind to H2-kb or
H2-Db molecules. Salmonella cells were transformed with murine
gp100 cDNA (SL-gp100) or with a fusion construct of gp100 and a
fragment of invariant chain cDNA (SL-gp00/Ii). Retardation of murine
B16F1 melanoma growth was more efficiently achieved by vaccination with
SL-gp100 than with the dendritic cells. Indeed, the efficacy of
vaccination was limited by tumor-induced immunosuppression.
The ability of Salmonella, Clostridia,
and other anaerobic bacteria to target tumors for their preferential
replication, leading to tumor regression, was taken advantage of in a
very interesting study reported by Dang et al. (7). It was previously demonstrated that a protozoan parasite, Toxoplasma gondii,
when injected into melanoma-bearing mice, caused tumor regression by
blocking angiogenesis (formation of blood vessels). It was thought that
inhibition of angiogenesis in the tumor was due to the production of
infection-induced antiangiogenic soluble factor(s) that created hypoxic
conditions in the tumors, leading to their necrosis (13). Since various anaerobic bacteria have been reported to allow tumor regression (7, 14) and since such bacteria proliferate mainly in the anaerobic core of the tumors, Dang et al. (7)
used the chemotherapeutic agent mitomycin C and the antivascular agent
dolastatin-10 in combination with the spores of an attenuated anaerobic
bacterium, Clostridium novyi, to treat colorectal cancer cells.
The rationale behind this combined therapy (called combination
bacteriolytic therapy or COBALT) was that, while the anaerobic bacteria
grew in the anaerobic zone of the core of the tumors, the antivascular
agent would create more extensive hypoxic areas for bacterial growth and
starve the tumors of oxygen and essential nutrients while the
chemotherapeutic agent attacked the tumor cells in the well-perfused,
nonnecrotic outside cells of the tumors, leading to their total
destruction (7, 14).
The results of such a study were highly impressive. In the absence of
the bacteria, but in the presence of mitomycin C and dolastatin-10, the
tumors persisted for a much longer time and showed limited regression,
while inclusion of the bacteria led to extensive disappearance of the
tumors within a short period of time and, in some cases, complete
dissolution of the tumors, leaving the animals tumor free. Similar
results were shown with a melanoma tumor cell line (7).
A downside of this combination therapy was the high level of toxicity,
where 15 to 45% of the mice died within a few days after the treatment
started, presumably due to the release of the highly toxic metabolic
products of the disintegrating tumors (7).
Bacterial products in the treatment of cancer.
A
lack of predictability of efficacy, a strong immune response, and the
associated side effects and toxicity have often limited the use of live
bacteria in the treatment of cancer. Preparations of microbial products,
the lipopolysaccharide (LPS) vaccines in particular, have also been
shown to have an anticancer property. As early as 1944, the endotoxin of
Serratia marcescens was shown to be the “hemorrhage-producing factor” that promoted tumor regression (29). Many subsequent reports have shown the varying effectiveness of certain detoxified bacterial LPS preparations (23, 28, 32), with or without additional components, including some preparations of the LPS vaccines of Pseudomonas aeruginosa (4)
that provided significant prolongation of remission and survival in
patients with acute myelogenous leukemia compared to patients not
treated with the LPS (4). A couple of macrolides, epothilone A and epothilone B (EpoA and EpoB), from the myxobacterium Sorangium cellulosum
and particularly a chemically modified synthetic form of EpoB,
desoxyepothilone B, have been shown to have antitumor activity against a
range of human tumors (3a).
More
recently, purified redox proteins such as azurin have been shown to
allow cancer regression in nude mice harboring human melanoma (39). Azurin is a copper-containing oxidoreductase that is normally involved in denitrification in P. aeruginosa. Yamada et al. (39)
demonstrated that azurin enters into the cytosol of a human melanoma
cell line (UISO-Mel-2), is transported to the nucleus, and forms a
complex with the tumor suppressor protein p53, thereby stabilizing it.
Stabilization of p53 allows the significant generation of reactive
oxygen species, which is a potent inducer of apoptosis (11, 38). Indeed, antioxidants that scavenge reactive oxygen species significantly reduce azurin-mediated cytotoxicity (11, 38).
p53 is normally a labile protein with a half-life of a few minutes. It
acts primarily as a transcriptional regulator within the cell, although
its role in nontranscriptional processes and various instances of cell
networking is also well known (35).
The two primary functions of p53 within the cell are to allow growth
arrest and to induce apoptosis in cells. Stabilization of p53 in
azurin-treated cells enhances the level of intracellular p53, which
triggers apoptosis in the melanoma cells xenotransplanted in nude mice,
leading to their in vivo regression (39).
Concluding remarks.
While
the ability of many attenuated bacteria to cause tumor regression has
been well known for many years, the exact mode of their action was
unknown. It has generally been believed that bacteria activate the
immune system upon entry to the host cells and that the activated immune
system then allows cancer regression. The experiments with T. gondii,
however, indicated that the inhibition of angiogenesis, rather than an
activated immune system, may contribute to cancer regression, at least
in the case of T. gondii (13). While the proliferation of anaerobic bacteria in the core of the tumors is a well-established fact (7, 25, 33),
there is very little understanding if such proliferating bacteria may
also secrete soluble factors that could contribute to cancer cell death.
The ability of purified azurin to mediate apoptosis in melanoma cells
thus begs the question of whether other bacteria similarly secrete other
proteins that may have cytotoxicity for cancer cells, somewhat similar
to the many antibiotics that bacteria produce to kill other bacteria or
fungi. Since azurin appears to act through complex formation with p53
and since 50% of human cancer cases have mutations in the p53 gene (35),
it remains to be seen if azurin will have any cytotoxic effects towards
these cancer cells as well. Similarly, it will be of great interest to
bacteriologists and to microbiologists in general to explore why
bacteria secrete redox proteins to kill mammalian cells. It has recently
been hypothesized (26) that both mammalian cell mitochondria and present-day bacteria such as P. aeruginosa
secrete redox proteins in response to certain signals (death signals
for mitochondria; presence of certain eukaryotic proteins in the case of
P. aeruginosa) that enter the mammalian cell cytosol, where
they normally are not present. Mitochondria are believed to have
prokaryotic ancestry, and therefore, the release of such redox proteins
to effect eukaryotic cell death is an evolutionarily conserved function.
The release of redox proteins, which are normally mitochondrion
specific, in the cytosol of the eukaryotic cell signals the cell to an
impending energy catastrophe, as mitochondria are the energy storehouse
of the cell and any release of mitochondrion-specific proteins in the
cytosol signals the loss of mitochondrial structural integrity. Since
the redox activity of azurin (11)
or other mammalian apoptogenic redox proteins such as AIF and PRG3 is
not important for the induction of apoptosis, it has been hypothesized
that the physical presence of the redox proteins in the cytosol is the
signal for the triggering of apoptosis. The eukaryotic cell has evolved
mechanisms that then initiate the apoptotic process through complex
formation of the redox proteins with specific cytosolic proteins such as
Apaf-1 and p53 (26).
It would be of great interest to know if bacterial redox proteins other
than azurin will enter the eukaryotic cell cytosol to trigger an
apoptotic event in such cells, including human cancer cells.
Acknowledgments
The
research in my laboratory is supported by Public Health Service grant
ES-04050-17 from the National Institute of Environmental Health Sciences
(NIEHS).
Notes
The views expressed in this Commentary do not necessarily reflect the views of the journal or of ASM.
REFERENCES
1. Agarwala, S. S., and J. M. Kirkwood. 1998. Adjuvant therapy of melanoma. Semin. Surg. Oncol. 14:302-310. [PubMed]
2. Alexandroff, A. D., A. M. Jackson, M. A. O'Donnell, and K. James. 1999. BCG immunotherapy of bladder cancer: 20 years on. Lancet 353:1689-1694. [PubMed]
3. Brandau, S., J. Riemensberger, M. Jacobsen, D. Kemp, et al. 2001. NK cells are essential for effective BCG immunotherapy. Int. J. Cancer 92:697-702. [PubMed]
3a. Chou, T.-C., X.-G. Zhang, A. Balog, D.-S. Su, K. Savin, J. R. Bertino, and S. J. Danishefsky.
1998. Desoxyepothilone B: an efficacious microtubule-targeted antitumor
agent with a promising in vivo profile relative to epothilone B. Proc. Natl. Acad. Sci. USA 95:9642-9647. [PMC free article] [PubMed]
4. Clarkson, B. D., M. D. Dowling, T. S. Gee, I. B. Cunningham, and A. H. Burchenal. 1975. Treatment of acute leukemia in adults. Cancer 36:775-795. [PubMed]
5. Coley, W. B. 1991. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin. Orthop. 262:3-13. [PubMed]
6. Cover, T. L., and M. J. Blaser. 1995. Helicobacter pylori: a bacterial cause of gastritis, peptic ulcer disease, and gastric cancer. ASM News 61:21-26.
7. Dang, L. H., C. Bettegowda, D. L. Huso, K. W. Kinzler, and B. Vogelstein. 2001. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. Natl. Acad. Sci. USA 98:15155-15160. [PMC free article] [PubMed]
8. Eisenstein, T. K., B. Bushnell, J. J. Meissler, Jr., N. Dalal, R. Schafer, and H. F. Havas. 1995. Immunotherapy of a plasmacytoma with attenuated Salmonella. Med. Oncol. 12:103-108. [PubMed]
9. Fox, M. E., M. J. Lemmon, M. L. Mauchline, T. O. Davis, A. J. Giaccia, N. P. Minton, and J. M. Brown. 1996. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered Clostridia. Gene Ther. 3:173-178. [PubMed]
10. Gill, G. V., and A. Holden. 1996. A malignant pleural effusion infected with Salmonella enteritidis. Thorax 51:104-105. [PMC free article] [PubMed]
11. Goto, M., T. Yamada, K. Kimbara, J. Horner, et al. 2003. Induction of apoptosis in macrophages by Pseudomonas aeruginosa
azurin: tumour-suppressor protein p53 and reactive oxygen species, but
not redox activity, as critical elements in cytotoxicity. Mol. Microbiol. 47:549-559. [PubMed]
12. Haley, J., D. Young, A. Alexandroff, K. James, and A. M. Jackson. 1999. Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-α. Immunology 96:114-121. [PMC free article] [PubMed]
13. Hunter, C. A., D. Yu, M. Gee, C. V. Ngo, et al. 2001. Systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J. Immunol. 166:5878-5881. [PubMed]
14. Jain, R. K., and N. S. Forbes. 2001. Can engineered bacteria help control cancer? Proc. Natl. Acad. Sci. USA 98:14748-14750. [PMC free article] [PubMed]
15. Lamm, D. L., D. E. Thor, S. C. Harris, J. A. Reyna, V. D. Stogdill, and H. M. Radwin. 1980. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J. Urol. 124:38-40. [PubMed]
16. Lamm, D. L., D. R. Riggs, J. S. Shriver, P. F. van Gilder, J. F. Rach, and J. I. DeHaven. 1994. Megadose vitamins in bladder cancer: a double-blind clinical trial. J. Urol. 151:21-26. [PubMed]
17. Matsumoto, M., T. Seya, S. Kikkawa, S. Tsuji, et al.
2002. Interferon gamma-producing ability in blood lymphocytes of
patients with lung cancer through activation of the innate immune system
by BCG cell wall skeleton. Int. Immunopharmacol. 1:1559-1569. [PubMed]
18. Morales, A., D. Edinger, and A. W. Bruce. 1976. Intracavity Bacillus Calmette Guerin in the treatment of superficial bladder tumours. J. Urol. 116:180-183. [PubMed]
19. Nauts, H. C., W. E. Swift, and B. L. Coley.
1946. The treatment of malignant tumors by bacterial toxins as
developed by the late William B. Coley, M. D., reviewed in the light of
modern research. Cancer Res. 6:205-216. [PubMed]
20. O'Donnell, M. A., and W. C. DeWolf. 1995. Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer: new prospects for an old warhorse. Surg. Oncol. Clin. N. Am. 4:189-201. [PubMed]
21. Paglia, P., and C. A. Guzman. 1998. Keeping the immune system alerted against cancer. Cancer Immunol. Immunother. 46:88-92. [PubMed]
22. Pan, Z.-K., G. Ikonomidis, A. Lazenby, D. Pardoll, and Y. Paterson. 1995. A recombinant Listeria monocytogenes
vaccine expressing a model tumour antigen protects mice against lethal
tumour cell challenge and causes regression of established tumours. Nat. Med. 1:471-477. [PubMed]
23. Parr, I., E. Wheeler, and P. Alexander. 1973. Similarities of the antitumor actions of endotoxin, lipid A and double stranded RNA. Br. J. Cancer 27:370-389. [PMC free article] [PubMed]
24. Pawelek, J. M., S. Sodi, A. K. Chakraborty, J. J. Platt, et al. 2002. Salmonella pathogenicity island-2 and anticancer activity in mice. Cancer Gene Ther. 9:813-818. [PubMed]
25. Pawelek, J. M., K. B. Low, and D. Bermudes. 1997. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 57:4537-4544. [PubMed]
26. Punj, V., and A. M. Chakrabarty.
Redox proteins in mammalian cell death: an evolutionarily conserved
function in mitochondria and prokaryotes. Cell. Microbiol., in press. [PubMed]
27. Ratlift, T. L., J. K. Ritchey, J. J. Yuan, G. L. Andriole, and W. J. Catalona. 1993. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol. 150:1018-1023. [PubMed]
28. Ribi, E. E., D. L. Granger, K. C. Millner, and S. M. Strain. 1975. Tumor regression caused by endotoxins and mycobacterial fractions. J. Natl. Cancer Inst. 55:1253-1257. [PubMed]
29. Shear, M. J., and A. Perrault.
1944. Chemical treatment of tumors. IX: Reaction of mice with primary
subcutaneous tumors to injection of the hemorrhage-producing bacteria
polysaccharide. J. Natl. Cancer Inst. 4:461-476.
30. Shepherd, F. A. 1997. Alternative to chemotherapy and radiotherapy as adjuvant treatment for lung cancer. Lung Cancer 17:S121-S136. [PubMed]
31. Sizemore, D. R., A. A. Branstrom, and J. C. Sadoff. 1995. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 270:299-302. [PubMed]
32. Strausser, H. R., and L. A. Bober.
1972. Inhibition of tumor growth and survival of aged mice inoculated
with Moloney tumor transplants and treated with endotoxin. Cancer Res. 32:2156-2159. [PubMed]
33. Sznol, M., S. L. Lin, D. Bermudes, L.-M. Zheng, and I. King. 2000. Use of preferentially-replicating bacteria for the treatment of cancer. J. Clin. Investig. 105:1027-1030. [PMC free article] [PubMed]
34. Thanhauser, A., A. Bohle, B. Schneider, et al. 1995. The induction of Bacillus Calmette-Guerin-activated killer cells requires the presence of monocytes and T helper type-1 cells. Cancer Immunol. Immunother. 40:103-108. [PubMed]
35. Vogelstein, B., D. Lane, and A. J. Levine. 2000. Surfing the p53 network. Nature 408:307-310. [PubMed]
36. Weth, R., O. Christ, S. Stevanovic, and M. Zoler. 2001. Gene delivery by attenuated Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination. Cancer Gene Ther. 8:599-611. [PubMed]
37. Wood, D. W., J. C. Setubal, R. Kaul, D. E. Monks, J. P. Kitajima, V. K. Okura, et al. 2001. The genome of the natural genetic engineer Agrobacte-rium tumefaciens C58. Science 294:2317-2323. [PubMed]
38. Yamada, T., M. Goto, V. Punj, O. Zaborina, et al.
2002. The bacterial redox protein azurin induces apoptosis in J774
macrophages through complex formation and stabilization of the tumor
suppressor protein p53. Infect. Immun. 70:7054-7062. [PMC free article] [PubMed]
39. Yamada, T., M. Goto, V. Punj, O. Zaborina, et al. 2002. Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer. Proc. Natl. Acad. Sci. USA 99:14098-14103. [PMC free article] [PubMed]
Няма коментари:
Публикуване на коментар